Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding

European Journal of Immunology
J Bradford KlineNicholas C Nicolaides

Abstract

C1q-engagement with IgG and IgM type antibodies is the initiating step of classical complement-mediated immunity. The tumor shed antigen CA125 has been reported to have immunosuppressive effects on host tumor responses as well as commercially approved and experimental monoclonal antibody (mAb)-based therapeutic agents. To better understand this effect, molecular and cellular studies were carried out testing the ability of CA125 to perturb the classical complement pathway. Here, we show that patient-derived CA125 inhibits IgG1, IgG3, and IgM-mediated complement-dependent cytotoxicity (CDC) by perturbing antibody-Fc interaction with the C1q complement-initiating protein only in those mAbs that are directly bound by CA125. This mechanism was found to impact naturally generated IgM antibodies as well as experimental and clinically approved mAbs, such as farletuzumab and rituximab, respectively. These data support a role for CA125 in humoral immune suppression and as a potential mechanism by which tumors may possibly avoid host immune responses.

References

Sep 1, 1978·The Journal of General Virology·G S Turner
May 15, 1985·International Journal of Cancer. Journal International Du Cancer·T TaiD L Morton
Jul 1, 1981·Journal of Neurosurgery·J A GarsonP L Kornblith
Apr 5, 2001·The New England Journal of Medicine·M J Walport
Apr 12, 2001·The New England Journal of Medicine·M J Walport
Dec 17, 2003·The Journal of Biological Chemistry·Armin RumpAtsushi Miyajima
Dec 25, 2003·Leukemia & Lymphoma·Osnat BaireyMati Shaklai
Jun 30, 2005·Cancer Letters·William J MurdochAnna McDonnel Smedts
Dec 11, 2007·Nature Biotechnology·Jochen G Salfeld
Jun 30, 2009·Cancer Immunology, Immunotherapy : CII·Miriam ReuschenbachNicolas Wentzensen
Jan 22, 2010·Molecular Cancer·Jennifer A A GubbelsManish S Patankar
May 26, 2010·Molecular Cancer·Jennifer A BelisleManish S Patankar
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Oct 26, 2010·Biochemical and Biophysical Research Communications·Mariko OhtaHiroshi Nakada
Mar 3, 2012·Journal of Clinical Immunology·Caroline StaffGustav J Ullenhag
Aug 21, 2012·Advances in Experimental Medicine and Biology·Reinhard Schwartz-Albiez
Dec 3, 2013·Nature Chemical Biology·Jason E HudakCarolyn R Bertozzi
Nov 5, 2014·Frontiers in Immunology·Gestur VidarssonTheo Rispens
Feb 13, 2016·Frontiers in Microbiology·Alena JandaArturo Casadevall
Oct 13, 2017·European Journal of Immunology·Andrea CossarizzaJakob Zimmermann

❮ Previous
Next ❯

Citations

Jan 10, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Minghai ZhangYu Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Antibodies: Complement Activation

The complement system can be activated by antigen-associated antibody. In the classical pathway of complement activation, C1q, C4b, and C3b are all able to bind to the Fc portion of IgG or IgM. Find the latest research on antibodies and complement activation here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.